Industry participants are working to create novel drugs for the treatment of seizures. During the course of the projected period, this is anticipated to fuel market expansion for benzodiazepine medications. For instance, in September 2021, Neurelis, Inc., a neuroscience business focused on innovation, launched a clinical programme to examine the use of VALTOCO (diazepam nasal spray) as a seizure cluster treatment in children with epilepsy, aged two to five. The study is currently in the clinical trial's Phase I/II. By December 2022, the study is anticipated to be done. Over the course of the projection period, product approvals by regulatory agencies are anticipated to fuel market expansion for benzodiazepine medications.
The global Benzodiazepine Drugs Market is estimated to be valued at US$ 3,050.4 Mn in 2022 and is expected to exhibit a CAGR of 3.2% over the forecast period (2022-2030)
Market Leaders in the Benzodiazepine Drugs Industry:
F. Hoffmann-La Roche Ltd.
Roche Holding AG engages in the pharmaceuticals and diagnostics. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company was founded in 1959 and is based in Ahmedabad, India.
Mallinckrodt Pharmaceuticals
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company was founded in 1867 and is based in Dublin, Ireland.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. on December 2022, Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial, early and deep responses, and a manageable safety profile for elranatamab in heavily pretreated patients with advanced multiple myeloma.